A leading pharmaceutical company witnessed an 8 percent surge in its stock price after unveiling ambitious plans to achieve 20 percent revenue growth, coupled with expectations of improved margins. The upbeat outlook has sparked strong investor interest, reflecting confidence in the company’s growth trajectory and operational efficiency.
Supriya Lifescience Ltd is eyeing consistent expansion over the coming years, with Managing Director Saloni Wagh forecasting annual revenue growth of over 20 percent.
“That’s the guidance I would like to give moving forward, 20 percent growth in revenue while maintaining a very robust EBITDA margin,” Wagh told CNBC-TV18 following the company’s Q4 FY25 earnings announcement.
For the quarter ended March 2025, Supriya Lifescience posted a 16.4 percent increase in revenue year-on-year to Rs.184.1 crore. Profit after tax rose by 36.4 percent to Rs.50.4 crore, and margins improved to 36.7 percent from 35.1 percent in Q4 FY24, representing one of the firm’s strongest operational results.
Still, Wagh noted that margins are likely to normalize in the upcoming quarters, settling between 33 and 35 percent. “Although it looks like a compression in percentage margin, in terms of absolute EBITDA and PAT, you will see good growth,” she explained, pointing to momentum in new product introductions and the expansion of its finished formulation contract manufacturing business.
Business Highlights
Supriya Lifescience operates a robust manufacturing infrastructure that includes 5 dedicated manufacturing blocks and 9 clean rooms to ensure high-quality production standards. The facility boasts a reactor capacity of 932 KLPD (kilolitres per day) and spans a total land area of 33,000 square metres, supporting large-scale pharmaceutical manufacturing and expansion potential.
Supriya Lifescience has a strong global regulatory presence, with 18 USDMF filings and 10 CEP approvals. The company has also secured 10 CADIFA approvals in Brazil, 5 KDMF filings in Korea, and 3 NMPA approvals in China, demonstrating its compliance with key international pharmaceutical standards and its readiness to serve major global markets.
Future Outlook
Supriya Lifescience is actively strengthening its innovation pipeline with two new R&D centres in Lote Parshuram and Ambernath, aimed at advancing lifecycle management, backward integration, and new product development. The centres will also support the identification and development of APIs, with a focus on anti-diabetic and anesthetic segments.
The company is expanding its global footprint, serving over 1,500 customers across more than 120 countries. It has initiated regulatory processes for product registrations and is targeting high-potential regions including North America, Japan, Australia, and New Zealand to drive further growth.
To meet rising demand, Supriya has significantly increased its reactor capacity by over 55 percent with the commissioning of a new production block. It is also tapping into the CMO/CDMO space, with a major European contract already secured, expected to contribute Rs.60 crores annually from FY27.
Financial Performance
Supriya Lifescience Ltd reported consolidated revenue of Rs.184 crores in Q4 FY25, reflecting a 16.5 percent increase year-on-year from Rs.158 crores in Q4 FY24. Sequentially, revenue declined slightly by 1.1 percent from Rs.186 crores in Q3 FY25.
Net profit for Q4 FY25 stood at Rs.50 crores, marking a strong 35.1 percent rise compared to Rs.37 crores in Q4 FY24. Compared to Q3 FY25, net profit increased by 6.4 percent from Rs.47 crores.
During Thursday’s trading session, the shares of Supriya Lifescience Ltd reached an intraday high of Rs.782.50 per share, rising 8.2 percent from the previous close of Rs.722.75 per share. The stock retreated from the peak and closed at Rs.751.60 per share. Over the past year, the shares have delivered over 120 percent returns.
Written by – Siddesh S Raskar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
